X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs LUPIN - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA LUPIN SUN PHARMA/
LUPIN
 
P/E (TTM) x 24.9 41.4 60.2% View Chart
P/BV x 2.6 2.5 103.5% View Chart
Dividend Yield % 0.5 0.7 73.4%  

Financials

 SUN PHARMA   LUPIN
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
LUPIN
Mar-18
SUN PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs7011,465 47.8%   
Low Rs433727 59.6%   
Sales per share (Unadj.) Rs110.4349.6 31.6%  
Earnings per share (Unadj.) Rs11.05.6 197.5%  
Cash flow per share (Unadj.) Rs17.229.6 58.3%  
Dividends per share (Unadj.) Rs2.005.00 40.0%  
Dividend yield (eoy) %0.40.5 77.3%  
Book value per share (Unadj.) Rs158.8300.3 52.9%  
Shares outstanding (eoy) m2,399.26452.08 530.7%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x5.13.1 163.8%   
Avg P/E ratio x51.6197.2 26.2%  
P/CF ratio (eoy) x32.937.1 88.8%  
Price / Book Value ratio x3.63.6 97.8%  
Dividend payout %18.290.0 20.3%   
Avg Mkt Cap Rs m1,360,021495,502 274.5%   
No. of employees `00017.817.0 104.4%   
Total wages/salary Rs m53,67128,647 187.4%   
Avg. sales/employee Rs Th14,890.99,273.6 160.6%   
Avg. wages/employee Rs Th3,017.11,681.0 179.5%   
Avg. net profit/employee Rs Th1,480.6147.4 1,004.2%   
INCOME DATA
Net Sales Rs m264,895158,042 167.6%  
Other income Rs m8,3881,504 557.9%   
Total revenues Rs m273,282159,545 171.3%   
Gross profit Rs m56,08131,475 178.2%  
Depreciation Rs m14,99810,859 138.1%   
Interest Rs m5,1762,044 253.3%   
Profit before tax Rs m44,29520,076 220.6%   
Minority Interest Rs m0-71 0.0%   
Prior Period Items Rs m035 0.0%   
Extraordinary Inc (Exp) Rs m-9,505-14,644 64.9%   
Tax Rs m8,4522,885 293.0%   
Profit after tax Rs m26,3382,513 1,048.2%  
Gross profit margin %21.219.9 106.3%  
Effective tax rate %19.114.4 132.8%   
Net profit margin %9.91.6 625.4%  
BALANCE SHEET DATA
Current assets Rs m316,359122,095 259.1%   
Current liabilities Rs m198,64350,956 389.8%   
Net working cap to sales %44.445.0 98.7%  
Current ratio x1.62.4 66.5%  
Inventory Days Days9585 112.1%  
Debtors Days Days108120 89.8%  
Net fixed assets Rs m213,178129,876 164.1%   
Share capital Rs m2,399904 265.4%   
"Free" reserves Rs m378,606134,866 280.7%   
Net worth Rs m381,006135,771 280.6%   
Long term debt Rs m17,72164,245 27.6%   
Total assets Rs m643,028263,054 244.4%  
Interest coverage x9.610.8 88.3%   
Debt to equity ratio x00.5 9.8%  
Sales to assets ratio x0.40.6 68.6%   
Return on assets %4.91.7 283.0%  
Return on equity %6.91.9 373.5%  
Return on capital %10.03.7 269.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m40,81653,141 76.8%   
Fx outflow Rs m30,14319,335 155.9%   
Net fx Rs m10,67333,807 31.6%   
CASH FLOW
From Operations Rs m39,07217,512 223.1%  
From Investments Rs m-33,708-14,073 239.5%  
From Financial Activity Rs m-15,393-14,921 103.2%  
Net Cashflow Rs m-7,359-11,482 64.1%  

Share Holding

Indian Promoters % 63.7 46.6 136.7%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 5.1 11.3 45.4%  
FIIs % 23.0 31.9 72.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 10.1 82.2%  
Shareholders   133,026 98,259 135.4%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  ELDER PHARMA  NOVARTIS  PANACEA BIOTECH  

Compare SUN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Modi's Victory Creates Sensex History; Ache Din Ahead?(Podcast)

Throughout the week, one slogan that took over the market and country as a whole was, Ab ki baar phir Modi Sarkar.

Related Views on News

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Indian Steel: The Perfect Multibagger Opportunity(Profit Hunter)

May 17, 2019

A structurally strong Indian Steel Industry will help India achieve 8%+ GDP growth in the coming years.

My Top 7 Stocks to Buy as Modi Returns to Power(The 5 Minute Wrapup)

May 23, 2019

The Modi government is all set to come back to power. With a stable government at the centre, how should you play the stock market?

What Makes TVS Srichakra and CCL Products a Cut Above the Rest?(The 5 Minute Wrapup)

May 17, 2019

Despite the commodity nature of their businesses, these two stocks have rewarded shareholders well.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


May 24, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS